NASDAQ:ABUS

Arbutus Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy ABUS

*Your capital is at risk

$4.26

-0.220 (-4.91%)

At Close: Jun 02, 2026

Arbutus Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 74.97. In total, the insiders bought 15.12M and sold 239.19K ABUS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	74.97
● Buy	15.12M shares
● Sell	239.19K shares
82% Buy Activity Weak Positive Correlation
Buy Signal High Confidence Feb 02, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 74.97. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 24, 2025 Buy	Common Shares	Gline Matthew	Director	0 Value: $0
Feb 24, 2025 Buy	Common Stock J-Other	Androski Lindsay President And CEO	CEO / President	0 Value: $0
Feb 24, 2025 Buy	Common Stock J-Other	Beardsley Robert A	Director	0 Value: $0
Feb 24, 2025 Buy	Common Stock J-Other	Bishop Joseph E	Director	0 Value: $0
Feb 24, 2025 Buy	Common Stock J-Other	Hasija Anuj	Director	0 Value: $0
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Naftzger J. Christopher General Counsel And Cco	Officer	220 300 Value: $724.8K
Feb 14, 2025 Buy	Common Shares A-Award	Naftzger J. Christopher General Counsel And Cco	Officer	54 300 Value: $178.6K
Feb 14, 2025 Buy	Common Shares A-Award	Mcelhaugh Michael J. Interim President & CEO	CEO / President	177 000 Value: $582.3K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcelhaugh Michael J. Interim President & CEO	CEO / President	718 800 Value: $2.36M
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Hastings David C Chief Financial Officer	C-Suite Officer	365 800 Value: $1.20M
Feb 14, 2025 Buy	Common Shares A-Award	Hastings David C Chief Financial Officer	C-Suite Officer	90 100 Value: $296.4K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Sims Karen Chief Medical Officer	Officer	200 300 Value: $659.0K
Feb 14, 2025 Buy	Common Shares A-Award	Sims Karen Chief Medical Officer	Officer	49 300 Value: $162.2K
Feb 14, 2025 Buy	Common Shares A-Award	Sims Karen Chief Medical Officer	Officer	49 300 Value: $162.2K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Sims Karen Chief Medical Officer	Officer	200 300 Value: $659.0K
Feb 14, 2025 Buy	Common Shares A-Award	Hastings David C Chief Financial Officer	C-Suite Officer	90 100 Value: $296.4K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Hastings David C Chief Financial Officer	C-Suite Officer	365 800 Value: $1.20M
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcelhaugh Michael J. Interim President & CEO	CEO / President	718 800 Value: $2.36M
Feb 14, 2025 Buy	Common Shares A-Award	Mcelhaugh Michael J. Interim President & CEO	CEO / President	177 000 Value: $582.3K
Feb 14, 2025 Buy	Common Shares A-Award	Naftzger J. Christopher General Counsel And Cco	Officer	54 300 Value: $178.6K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Naftzger J. Christopher General Counsel And Cco	Officer	220 300 Value: $724.8K
Feb 04, 2025 Sell	Common Shares S-Sale	Hastings David C Chief Financial Officer	C-Suite Officer	22 183 Value: $72.8K
Feb 04, 2025 Sell	Common Shares S-Sale	Sims Karen Chief Medical Officer	Officer	19 348 Value: $63.5K
Feb 04, 2025 Sell	Common Shares S-Sale	Mcelhaugh Michael J. Interim President & CEO	CEO / President	23 790 Value: $78.1K
Feb 04, 2025 Sell	Common Shares S-Sale	Naftzger J. Christopher General Counsel And Cco	Officer	11 333 Value: $37.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARBUTUS BIOPHARMA CORPORATION

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ...

Read Full Profile Here